APIs/Chemistry Outsourcing Cambridge Major Adds Significant API Production Capacity in the US
Chemistry Outsourcing specialists Cambridge Major plans significant capacity expansions for its Active Pharmaceutical Ingredient (API) manufacturing services in Germantown, Wisconsin. The expansion comes only three years after commissioning the new state-of-the-art facility, further validating CML’s business model of focused investment in US–based assets.
Germantown/Wisconsin, USA – “We are very pleased to report that our faith in the “invest in the West” policy initiated a few years ago continues to bear fruit,” commented Brian Scanlan, President & CEO. “Cambridge Major Laboratories (CML) is very well positioned to support both increasing demand for our commercial products as well as our healthy pipeline of API’s in later phases of clinical development.”
Investment Expands Capabilities of Outsourcing Specialist CML
The expansion will include significant additional reactor capacity as well as isolation equipment. Alongside capacity additions, the company has made additional investments in engineering controls to ensure the sustainability of the business. “Our Environmental, Health, and Safety commitments underpin all operations, and we have invested further containment capabilities with engineering controls across production trains. Additional containment capabilities will also be introduced into our European facility later this year,” added Scanlan.
Growing Trend for Pharmaceutical Outsourcing
Following the commissioning of the large scale API facility in 2009, CML has more recently invested in other supporting areas of the business, such as Solid State services and an expanded analytical offering. “CML is committed to becoming the long-term partner of choice for complex API development projects”, commented Roger McDonald, European Business Development Director.